Titan Pharmaceuticals, Inc.
TTNP
$3.70
-$0.09-2.38%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.54% | 63.55% | -97.45% | 46.19% | -482.84% |
| Total Depreciation and Amortization | -- | -100.00% | 50.00% | -33.33% | -88.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | 100.00% | 0.00% | -102.04% | 103.71% |
| Change in Net Operating Assets | 305.71% | 204.35% | -94.84% | 235.98% | -62.38% |
| Cash from Operations | 26.98% | 66.49% | -237.36% | 72.71% | -22.40% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 121.93% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | 121.05% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -95.54% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -95.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 18.04% | 66.49% | -237.36% | 54.12% | -116.73% |